Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation

Cancer

Volumn 82, Issue 8, 1998, Pages 1506-1512

  Salloum, Emile ^a   Jillella, Anand P ^a   Nadkarni, Rajani ^a   Seropian, Stuart ^a   Hu, Grace L ^b   D'Andrea, Elizabeth ^a   Zelterman, Daniel ^b   Cooper, Dennis L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

BEAM; Cardiac toxicity; High dose chemotherapy; Peripheral blood progenitor cell transplantation; Pulmonary toxicity

Indexed keywords

BLEOMYCIN; CARBON DIOXIDE; CARMUSTINE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PERTECHNETIC ACID TC 99M; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; MEDIASTINUM; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SCINTIANGIOGRAPHY; TOTAL LUNG CAPACITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; HEART; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LUNG; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; PODOPHYLLOTOXIN; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 0032523083     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980415)82:8<1506::AID-CNCR12>3.0.CO;2-8     Document Type: Article

References (33)

1. Phillip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
2. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomized trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-7.
3. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997;126:600-7.
4. Wheeler C, Antin JH, Hallowell C, Come SE, Smith BR, Bubley GJ, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990;8:648-56.
5. Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993;147:1264-70.
6. Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy after pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest 1995;107:482-7.
7. Valteau D, Hartmann O, Benhamou E, Caillaud JM, Brugieres L, Beaugean F, et al. Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation. Transplantation 1988; 45:737-40.
8. Jones RB, Matthes S, Shpall EJ, Fisher JH, Stemmer SM, Duffont C, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993;85:640-7.
9. Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Snnipper LE, et al. Pulmonary toxicity associated with high-dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant 1992;10:57-63.
10. Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 1996;17:335-40.
11. Weaver CH, Appelbaum FR, Petersen FB, Buckner CD. High-dose cytarabine, carmustine and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993;7:1329-35.
12. Pecego R, Hill R, Appelbaum FR, Amos D, Buckner CD, Ferer A, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986;42:515-7.
13. Jochelson M, Tarbell NJ, Freedman AS, Rabinowe SN, Takvorian T, Soiffer R, et al. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 1990;6:629-31.
14. Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, et al. Carmustine, Ara-C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study. Bone Marrow Transplant 1990;1994:14:595-600.
15. Ghalie R, Szidon J, Thompson L, Nawas YN, Dolce A, Kaizer H. Evaluation of pulmonary complications after bone marrow transplantation: the role of pretreatment pulmonary function tests. Bone Marrow Transplant 1992;10:359-65.
16. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995;15:549-55.
17. Callahan RJ, Froelich JW, McKusick KA, Leppo J, Strauss HW. A modified method for the in vivo labelling of red blood cells with Tc-99m: concise communication. J Nucl Med 1982;23:315-8.
18. Lee FA, Fetterman R, Zaret BL, Wackers FJTh. Rapid radionuclide derived systolic and diastolic cardiac function using cycle-dependent background correction and Fourier analysis. Proc Comput Cardiol September 1985:443-6.
19. Crapo RO, Morris AH, Gardner RM. References values for pulmonary tissue volume, membrane diffusing capacity, and pulmonary capillary blood volume. Bull Europ Physiopathol Resp 1982;18:893-9.
20. Ogilvie CM, Forster RE, Blakemore WS, Morton JW. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957;36:1-17.
21. Bates D, Macklem P, Christie R. An introduction to the integrated study of the lung. In: Bates D, Macklem P, Christie R, editors. Respiratory function in disease. Philadelphia: Saunders, 1971:93-4.
22. SAS Institute Inc. SAS Technical Report P-179: additional SAS/STAT procedures. Release 6.03. Cary, NC: SAS Institute Inc, 1988.
23. Durant JR, Norgord MJ, Murad TM, Bartolucci AA, Lang Ford KH. Pulmonary toxicity associated with bis-chloroethyl nitrosourea (BCNU). Ann Intern Med 1979;90:191-4.
24. Babson JR, Reed DJ. Inactivation of gluththione reductase by 2-chloroethyl nitrosourea-derived isocyanates. Biophys Res Commun 1978;83:754-62.
25. Friedman HS, Colvin OM, Aisaka K, Popp J, Bossen EH, Reimer KA, et al. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 1990;50:2455-62.
26. Peters WP, Rodeheaver DP, Menzel DB. Effects of high-dose alkylating agents on endomyocardial glutathione levels and cardiac performance in man. Proc Am Assoc Cancer Res 1988;29:268-73.
27. Kanj SS, Sharara AI, Shpall EJ, Jones RB, Peters WP. Myocardial ischemia associated with high-dose carmustine infusion. Cancer 1991;68:1910-2.
28. Corringham R, Gilmore M, Prentice HG, Boesen E. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 1983;52:1783-7.
29. Veins P, Maraninchi D, Legros M, Oberling F, Philip T, Herve P, et al. High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990;5:227-33.
30. Colombat P, Gorin NC, Lemonnier MP, Binet C, Laporte JP, Douay L, et al. The role of autologous bone marrow transplantation in 46 adults with non-Hodgkins lymphomas. J Clin Oncol 1990;8:630-7.
31. Wheeler C, Strwderman M, Ayash L, Churchill HW, Bierer BE, Elias A, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993;11:1085-91.
32. Henner WD, Peter WP, Eder JP, Amman K, Schnipper L, Frei E III. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep 1986;70:877-80.
33. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-8.